Lifecore Q2 Revenue Drops 20%, Preferred Redemption Crisis Looms with $50M Due in December
LFCR sits 25% above its 52-week low of $3.625.
Summary
Lifecore Biomedical's Q2 2026 10-Q reveals a 20% revenue decline, widening losses, and a $50.2 million preferred stock redemption due December 28 that it cannot fund without lender consent.
Key Events · Earnings and Guidance · LFCR
-
Revenue Plunges 20%
Total revenue fell to $57.4 million for the six months ended June 30, 2026, from $71.6 million a year ago. CDMO revenue dropped 29% to $31.3 million, driven by lower sales volumes and the absence of a prior-year take-or-pay arrangement.
-
Net Loss Widens to $21.1M
Net loss available to common stockholders reached $23.1 million, or $0.61 per share, compared to $17.7 million a year ago. The increase was fueled by $14.2 million in related-party interest expense and a $4.4 million non-cash charge from the debt derivative liability.
-
$50.2M Preferred Redemption Due December 28
All 49,263 shares of Series A Redeemable Convertible Preferred Stock have been submitted for redemption. The company must pay $50.2 million in cash by December 28, 2026, but has only $17.2 million in cash and cannot make the payment without lender consent, which it has not obtained.
-
Liquidity Crisis Deepens
With $17.2 million in cash and $21.6 million available under its revolver, Lifecore's liquidity is insufficient to cover the redemption. The company is evaluating strategic alternatives, including debt or equity financing, but warns internally generated cash will not be enough.
Analysis · LFCR · Life Sciences
Lifecore's Q2 results reveal a deepening financial crisis. Revenue fell 20% year-over-year, driven by a 29% plunge in CDMO sales, while net losses ballooned to $21.1 million. The real alarm is the preferred stock redemption: all 49,263 Series A shares have been put to the company, requiring a $50.2 million cash payment by December 28, 2026. With only $17.2 million in cash, Lifecore cannot make the payment without lender consent, which it does not yet have. Failure to redeem triggers a 1% monthly penalty interest on top of the 7.5% PIK dividend. Adding governance risk, the company also disclosed that its material weakness in internal controls remains unremediated. This filing confirms the worst-case scenario flagged by activist investors in July — the redemption clock is ticking with no clear solution.
At the time of this filing, LFCR was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.2M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.